



26 October 2021

Clinical Study Protocol

TL-895-202

EudraCT Number: 2020-002259-39

A Phase 1/2, Double-Blind, Randomized, Placebo- Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

This study was submitted and approved by the authorities; however, there were no patients enrolled in the European economic area; therefore, no report was created.

DocuSigned by:
John Mei
 Signer Name: John Mei
Signing Reason: I approve this document
Signing Time: 26-Oct-2021 | 11:01 AM PDT
4816A4E1650247EE8DF52D79A657AB28

John H M Mei

VP, Clinical Operations
Telios Pharma